AU2020377539B2 - Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor - Google Patents

Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor Download PDF

Info

Publication number
AU2020377539B2
AU2020377539B2 AU2020377539A AU2020377539A AU2020377539B2 AU 2020377539 B2 AU2020377539 B2 AU 2020377539B2 AU 2020377539 A AU2020377539 A AU 2020377539A AU 2020377539 A AU2020377539 A AU 2020377539A AU 2020377539 B2 AU2020377539 B2 AU 2020377539B2
Authority
AU
Australia
Prior art keywords
apabetalone
patients
mace
sglt2
rvx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020377539A
Other languages
English (en)
Other versions
AU2020377539A1 (en
Inventor
Christopher Ross Armstrong Halliday
Aziz Naeem KHAN
Kenneth Eugene Lebioda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resverlogix Corp
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of AU2020377539A1 publication Critical patent/AU2020377539A1/en
Application granted granted Critical
Publication of AU2020377539B2 publication Critical patent/AU2020377539B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2020377539A 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor Active AU2020377539B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930860P 2019-11-05 2019-11-05
US62/930,860 2019-11-05
PCT/IB2020/000912 WO2021090061A1 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (2)

Publication Number Publication Date
AU2020377539A1 AU2020377539A1 (en) 2022-05-19
AU2020377539B2 true AU2020377539B2 (en) 2025-05-29

Family

ID=75849803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020377539A Active AU2020377539B2 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Country Status (18)

Country Link
US (1) US12551484B2 (cg-RX-API-DMAC10.html)
EP (1) EP4054584B1 (cg-RX-API-DMAC10.html)
JP (1) JP7502811B2 (cg-RX-API-DMAC10.html)
KR (1) KR102935008B1 (cg-RX-API-DMAC10.html)
CN (1) CN114650824A (cg-RX-API-DMAC10.html)
AU (1) AU2020377539B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022008223A2 (cg-RX-API-DMAC10.html)
CA (1) CA3160147A1 (cg-RX-API-DMAC10.html)
DK (1) DK4054584T3 (cg-RX-API-DMAC10.html)
ES (1) ES3042146T3 (cg-RX-API-DMAC10.html)
FI (1) FI4054584T3 (cg-RX-API-DMAC10.html)
HU (1) HUE073043T2 (cg-RX-API-DMAC10.html)
IL (1) IL292696B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022005029A (cg-RX-API-DMAC10.html)
PL (1) PL4054584T3 (cg-RX-API-DMAC10.html)
PT (1) PT4054584T (cg-RX-API-DMAC10.html)
TW (1) TWI867086B (cg-RX-API-DMAC10.html)
WO (1) WO2021090061A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EP4236957A4 (en) * 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
WO2022155303A1 (en) * 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091029A1 (en) * 2020-10-30 2022-05-05 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CN106075451A (zh) 2009-05-27 2016-11-09 阿斯利康(瑞典)有限公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
BR112016003584A8 (pt) 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
KR20160043118A (ko) 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
MA43037A (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Inst Inc Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
JP6849804B2 (ja) 2016-12-09 2021-03-31 クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
US11419883B2 (en) 2017-05-05 2022-08-23 The Regents Of The University Of California Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
KR20220124736A (ko) 2020-01-08 2022-09-14 리스버로직스 코퍼레이션 Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091029A1 (en) * 2020-10-30 2022-05-05 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Also Published As

Publication number Publication date
TWI867086B (zh) 2024-12-21
CN114650824A (zh) 2022-06-21
US12551484B2 (en) 2026-02-17
EP4054584A4 (en) 2023-11-08
MX2022005029A (es) 2022-07-12
TW202131924A (zh) 2021-09-01
KR20220098757A (ko) 2022-07-12
IL292696B2 (en) 2026-05-01
CA3160147A1 (en) 2021-05-14
IL292696B1 (en) 2026-01-01
KR102935008B1 (ko) 2026-03-09
EP4054584A1 (en) 2022-09-14
JP7502811B2 (ja) 2024-06-19
IL292696A (en) 2022-07-01
US20220370452A1 (en) 2022-11-24
ES3042146T3 (en) 2025-11-18
DK4054584T3 (en) 2025-09-01
FI4054584T3 (fi) 2025-08-22
HUE073043T2 (hu) 2025-12-28
AU2020377539A1 (en) 2022-05-19
JP2023500685A (ja) 2023-01-10
BR112022008223A2 (pt) 2022-09-06
PL4054584T3 (pl) 2025-11-03
EP4054584B1 (en) 2025-07-09
PT4054584T (pt) 2025-07-16
WO2021090061A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
EP4054584B1 (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
KR102011641B1 (ko) 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
JP7763761B2 (ja) Betブロモドメイン阻害剤およびジペプチジルペプチダーゼ4阻害剤の組合せによる主要有害心血管イベント(mace)の治療方法および/または予防方法
AU2021368618B2 (en) Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US20230398137A1 (en) Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
HK40081394A (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
HK40081394B (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EA047426B1 (ru) Способы лечения и/или предотвращения серьезных нежелательных сердечно-сосудистых явлений (снсся) с помощью комбинации ингибитора бромодомена bet и ингибитора натрий-глюкозного котранспортера 2-го типа
EA049336B1 (ru) Способы улучшения функции почек при помощи комбинации ингибитора бромодомена bet и ингибитора натрий-зависимого транспортера глюкозы 2 типа
WO2015134357A1 (en) Modulators of insulin receptor

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LEBIODA, KENNETH EUGENE; HALLIDAY, CHRISTOPHER ROSS ARMSTRONG AND KHAN, AZIZ NAEEM

FGA Letters patent sealed or granted (standard patent)